CircuLite will develop its right-heart circulatory support system based on Synergy Micro-pump used to treat right heart failure due to pulmonary arterial hypertension (PAH) and other causes.
CircuLite is also using the fund to conduct a clinical trial with Synergy in patients with Class IIIB/early Class IV heart failure at multiple centers in Europe, aimed at achieving CE Mark.
CircuLite president and CEO Paul Southworth said the ongoing CE Mark study has shown that providing supplemental flow with Synergy unloads the left ventricle and improves hemodynamics, which can translate into important improvements in functional status and quality of life.
"We believe that modifying Synergy for right-heart support could be similarly beneficial and we look forward to further progress our development of a right-heart system to address the needs of patients with PAH," Southworth said.
